Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its core products include Vafseo, an oral treatment for anemia due to chronic kidney disease (CKD) in dialysis patients, and Auryxia, an oral medicine for hyperphosphatemia and iron deficiency anemia in CKD patients. Akebia leverages hypoxia-inducible factor (HIF) science and targets nephrology markets through direct sales and partnerships globally.
This description was generated via AI from an annual report. Updated about 1 year ago.